Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2017/12/010998
CTRI/2017/12/010998CompletedPhase 2

A Clinical Study to Evaluate the Efficacy and Safety of Habb-i Hindi (O) and Habb-i Baras (L) in the Management of Baras (Vitiligo)

Central Research Institute of Unani Medicine0 sites60 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Patients of any sex in the age group between 18 and 40 Years Patients with NonSegmental Vitiligo (NSV), disease chronicity from 6 months to 2 years
  • •Vitiligo involving more than 2% Body Surface Area (BSA)
  • •Patients with less than 5 New Lesions in the last month
  • •Patients with less than 15 lesions in the last 3 months
  • •Patients who have not received systemic treatment within 4 weeks prior to study entry
  • •Patients who have not received topical treatment within 2 weeks prior to study entry

Exclusion Criteria

  • •Patients aged less than 18 years or more than 40 years
  • •Pregnant or Lactating Women
  • •Segmental Vitiligo (SV), liptip, or universal Vitiligo, or Vitiligo with leucotrichia
  • •History of Photosensitivity/Photoexaggerated Dermatoses and Connective Tissue Diseases
  • •Significant Pulmonary/Cardiovascular/Hepatorenal Dysfunction 6. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (Cutaneous or Internal)
  • •Patient not willing to attend treatment schedule regularly
  • •Patients not having a suitable facility for sun exposure

Investigators

Similar Trials

Not yet recruiting
Phase 2
Treatment of ithy, red, dry and cracked skin condition (Eczema) by of Unani drug
CTRI/2017/12/010957Central Research Institute of Unani Medicine
Completed
Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of JR-031 in Patients with Epidermolysis BullosaEpidermolysis Bullosa
JPRN-UMIN000026645Osaka University6
Recruiting
Not Applicable
Evaluation of the usefulness and safety of the combined use of an ear prosthesis and a cartilage conduction hearing aid
JPRN-UMIN000044711Keio University30
Completed
Phase 2
Clinical comparative efficacy and safety of Polyherbal Unani formulations.
CTRI/2023/02/049696State Unani Medical College, himmatganj Prayagraj40
Not yet recruiting
Phase 2
Effectiveness of Unani Drugs in High Blood Pressure
CTRI/2017/12/011006Central Research Institute of Unani Medicine